recently evaluated potential candidate genes that may be prioritized for gene therapy in humans based on critical criteria like gene size, timing of cochlear degradation, cell types of primary expression, availability of mouse models and efficacy of AAV delivery in those mice, and human hearing loss severity, onset, and prevalence.[111] They identified three genes, TMPRSS3,[112]PCDH15,[113] and TMC1,[114, 115, 116] that satisfy all criteria from a list of 93 non‐syndromic hearing loss genes. This evidence concerns the gene TMC1 and hearing loss disorder.